In Silico as Regulatory Evidence in EU

This exclusive interactive session explores the shifting tides of the European regulatory landscape. Our primary focus is to address a critical question for our community: “How is in silico evidence currently perceived by regulators?“. As Europe undergoes significant legislative transitions, this session will provide a comprehensive summary of recent evolutions. We will analyse how in silico evidence is being considered and integrated within the Pharma and MedTech sectors.

Beyond providing updates, this meeting is designed to be a catalyst for community engagement. We aim to share tangible calls to action and collaboratively identify opportunities to leverage direct engagement with legislators and regulators.

Watch the full Briefing Session recording – now publicly available after an initial period reserved for VPH members.

VPH members benefit from exclusive early access to time-sensitive content and community insights. If you’d like to stay ahead and access future materials as soon as they are released, we invite you to explore our membership plans and their benefits. Already a member? Make sure your membership is renewed for 2026 by logging into your personal account. For any clarifications you might need, please visit our FAQ  or contact us.

WATCH HERE 

We are also pleased to share the presentation from the session, which is available at the following link.